Biotech Values

[vinmantoo]

I expect ENTA to seek an FDA buy-in to run a pivotal phase-2/3 trial, instead of a straight phase-2. The FDA may not concur with such a plan, but they would (IMO) be derelict in not doing so, given the potential utility of EDP-235 in mitigating the pandemic.

That would make me happy and obviously hasten the potential approval time.

If ENTA does get an FDA buy-in to run a pivotal phase-2/3, then a partnership deal up-front becomes considerably more likely, IMO.

I figured we would get at least a $5-$10 price increase if the safety and pharmacokinetic data was good so my guestimate is no so bad. The fully realized rise may take a few days given how lightly traded ENTA is. Given it is friday, today's close could be quite interesting. In any event. I nibbled and bought a little more today after the data release. Obviously a partnership deal would drive ENTA stock price much higher. Nice way to start the weekend.